Last Updated: August 14, 2026

Details for Patent: 7,538,108


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,538,108
Title:Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract:The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds of structural formula shown below, compositions comprising these compounds, intermediates and methods for synthesizing these compounds, and methods of using these compounds in a variety of applications including treatment of autoimmune diseases.
Inventor(s):Rajinder Singh, Esteban Masuda, Somasekhar Bhamidipati, Thomas Sun, Valentino J. Stella
Assignee: Rigel Pharmaceuticals Inc
Application Number:US11/453,731
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,538,108

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 AB RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT ⤷  Start Trial
Rigel Pharms TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,538,108

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1856135 ⤷  Start Trial 301039 Netherlands ⤷  Start Trial
European Patent Office 1856135 ⤷  Start Trial CA 2020 00018 Denmark ⤷  Start Trial
European Patent Office 1856135 ⤷  Start Trial LUC00153 Luxembourg ⤷  Start Trial
European Patent Office 1856135 ⤷  Start Trial 122020000021 Germany ⤷  Start Trial
European Patent Office 1856135 ⤷  Start Trial PA2020507 Lithuania ⤷  Start Trial
European Patent Office 1856135 ⤷  Start Trial 132020000000046 Italy ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.